Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 145Lymphoma 104Lymphoma, Large B-Cell, Diffuse 76Sarcoma 62Hodgkin Disease 46Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Burkitt Lymphoma 35Triple Negative Breast Neoplasms 31Lymphoma, Non-Hodgkin 29Lymphoma, Mantle-Cell 27Leukemia 25Neoplasms 22Lymphoma, Follicular 22Neoplasm Metastasis 21Multiple Myeloma 21Neuroblastoma 20Carcinoma, Hepatocellular 18Ovarian Neoplasms 16Lymphoma, B-Cell 16Liver Neoplasms 14Urinary Bladder Neoplasms 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Osteosarcoma 12Lymphoma, T-Cell, Peripheral 11Lymphoma, Large-Cell, Anaplastic 11Inflammatory Breast Neoplasms 11Breast Neoplasms, Male 11Prostatic Neoplasms 10Dendritic Cell Sarcoma, Interdigitating 10Lymphoma, Large-Cell, Immunoblastic 9

Interventions

trebananib 1selurampanel 1saracatinib 1perifosine 1elacestrant 1Trabectedin 1Thalidomide 1Temozolomide 1Sunitinib 1RAD1901 1Postmortem Imaging 1Paclitaxel 1Mass Spectrometry 1Magnetic Resonance Spectroscopy 1Injections 1Imatinib Mesylate 1Ifosfamide 1High-Energy Shock Waves 1Fulvestrant 1Doxorubicin 1Chromatography, High Pressure Liquid 1Biopsy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Endometrial Stromal × Doxorubicin × Clear all
NCT06277154 2025-07-24

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

HRYZ Biotech Co.

Phase 2 Recruiting
148 enrolled
GynecologicSarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Endometrial Stromal, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡